Related Experiment Video
Updated: May 5, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
F Hayakawa1, K Sugimoto, Y Harada
1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Abstract:
Signal transduction and activator of transcription (STAT) proteins are extracellular ligand-responsive transcription factors that mediate cell proliferation, apoptosis, differentiation, development and the immune response. Aberrant signals of STAT induce uncontrolled cell proliferation and apoptosis resistance and are strongly involved in cancer. STAT has been identified as a promising target for antitumor drugs, but to date most trials have not been successful. Here, we demonstrated that a novel STAT inhibitor, OPB-31121, strongly inhibited STAT3 and STAT5 phosphorylation without upstream kinase inhibition, and induced significant growth inhibition in various hematopoietic malignant cells. Investigation of various cell lines suggested that OPB-31121 is particularly effective against multiple myeloma, Burkitt lymphoma and leukemia harboring BCR-ABL, FLT3/ITD and JAK2 V617F, oncokinases with their oncogenicities dependent on STAT3/5. Using an immunodeficient mouse transplantation system, we showed the significant antitumor effect of OPB-31121 against primary human leukemia cells harboring these aberrant kinases and its safety for normal human cord blood cells. Finally, we demonstrated a model to overcome drug resistance to upstream kinase inhibitors with a STAT inhibitor. These results suggested that OPB-31121 is a promising antitumor drug. Phase I trials have been performed in Korea and Hong Kong, and a phase I/II trial is underway in Japan.
Insights
A novel Signal Transduction and Activator of Transcription (STAT) inhibitor, OPB-31121, effectively targets STAT3 and STAT5 phosphorylation, showing significant antitumor effects in various hematopoietic malignancies. This drug demonstrates promise in overcoming resistance to existing therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Signal Transduction and Activator of Transcription (STAT) proteins regulate critical cellular processes.
- Aberrant STAT signaling is implicated in various cancers, making STAT a target for antitumor drugs.
- Previous STAT inhibitor trials have yielded limited success.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel STAT inhibitor, OPB-31121, against hematopoietic malignancies.
- To investigate OPB-31121's mechanism of action and its potential to overcome drug resistance.
Main Methods:
- In vitro assessment of OPB-31121's inhibition of STAT3 and STAT5 phosphorylation in cancer cell lines.
- In vivo efficacy and safety evaluation using an immunodeficient mouse transplantation model with primary human leukemia cells.
- Analysis of OPB-31121's effectiveness against specific oncogenic kinases dependent on STAT3/5.
Main Results:
- OPB-31121 demonstrated potent inhibition of STAT3 and STAT5 phosphorylation without affecting upstream kinases.
- Significant growth inhibition was observed in multiple myeloma, Burkitt lymphoma, and leukemia cell lines harboring specific oncogenic kinases.
- OPB-31121 showed significant antitumor effects in vivo against human leukemia cells and was safe for normal human cord blood cells.
- A model was proposed to overcome drug resistance to upstream kinase inhibitors using OPB-31121.
Conclusions:
- OPB-31121 is a promising novel STAT inhibitor with significant antitumor activity against various hematopoietic malignancies.
- The drug's ability to inhibit STAT3/5 phosphorylation and overcome resistance mechanisms warrants further clinical investigation.
- Phase I and ongoing Phase I/II trials support OPB-31121's potential as an effective antitumor therapeutic.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:34Inhibition of Cdk Activity
01:10Drugs that Destabilize Microtubules
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...